Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings.
OBJECTIVE
The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacement (TAVR) is a less invasive replacement method. The objective was to estimate cost-effectiveness of TAVR via transfemoral access vs MM in surgically inoperable patients with severe AS from the Canadian public healthcare system perspective.


METHODS
A cost-effectiveness analysis of TAVR vs MM was conducted using a deterministic decision analytic model over a 3-year time horizon. The PARTNER randomized controlled trial results were used to estimate survival, utilities, and some resource utilization. Costs included the valve replacement procedure, complications, hospitalization, outpatient visits/tests, and home/nursing care. Resources were valued (2009 Canadian dollars) using costs from the Ontario Case Costing Initiative (OCCI), Ontario Ministry of Health and Long-Term Care and Ontario Drug Benefits Formulary, or were estimated using relative costs from a French economic evaluation or clinical experts. Costs and outcomes were discounted 5% annually. The effect of uncertainty in model parameters was explored in deterministic and probabilistic sensitivity analysis.


RESULTS
The incremental cost-effectiveness ratio (ICER) was $32,170 per quality-adjusted life year (QALY) gained for TAVR vs MM. When the time horizon was shortened to 24 and 12 months, the ICER increased to $52,848 and $157,429, respectively. All other sensitivity analysis returned an ICER of less than $50,000/QALY gained.


CONCLUSIONS
A limitation was lack of availability of Canadian-specific resource and cost data for all resources, leaving one to rely on clinical experts and data from France to inform certain parameters.


CONCLUSIONS
Based on the results of this analysis, it can be concluded that TAVR is cost-effective compared to MM for the treatment of severe AS in surgically inoperable patients.
OptumInsight, Burlington, Ontario, Canada. rebeccalhancock@hotmail.com
Rebecca L
RL
Hancock-Howard
Christopher M
CM
Feindel
Josep
J
Rodes-Cabau
John G
JG
Webb
Ann K
AK
Thompson
Kurt
K
Banz
D001024:Aortic Valve Stenosis / Q000601:surgery*; D002170:Canada; D003362:Cost-Benefit Analysis; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data*; D019918:Heart Valve Prosthesis Implantation / Q000191:economics* / Q000379:methods; D006760:Hospitalization / Q000191:economics; D006801:Humans; D018803:Models, Economic; D062072:Patient Acuity; D011183:Postoperative Complications / Q000191:economics; D019057:Quality-Adjusted Life Years; D016019:Survival Analysis